ArticleJournal of geriatric cardiology : JGC2026
Integrated drug management for elderly patients with congestive heart failure: enhancing medication accuracy using the MINE (Medicine IN gEriatric) application.
Article in Journal of geriatric cardiology : JGC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study evaluated the impact of the Medicine IN Geriatric (MINE) application, which integrates the Integrated Medicine Management (IMM) model and STOPP/START criteria, on improving prescribing practices in elderly patients with congestive heart failure (CHF). Methods: A two-phase study was conducted: validation of the IMM model and its implementation via the MINE app. A quasi-experimental pretest-posttest control group design was used in a hospital in East Kalimantan, Indonesia. Patients aged 60-79 years were randomly assigned to the intervention or control group. The intervention group received IMM-based pharmaceutical services, including medication reconciliation, repeated medication reviews, and individualized discharge counseling. The outcomes assessed included polypharmacy rates, potentially inappropriate medications (PIMs), potential prescribing omissions (PPOs), and health-related quality of life, using the EQ-5D-5L and EQ-VAS tools. Results: Expert validation showed high content validity, with I-CVI ≥ 0.86 and S-CVI = 0.94. During implementation, the use of antiplatelets, statins, angiotensin converting enzyme inhibitors (ACEI), and angiotensin receptor β-blockers (ARB) declined from admission to discharge. PIMs, such as beta-blockers in patients with conduction disorders and ACE-I/ARBs in those with hyperkalemia, also decreased. The intervention group's EQ-5D-5L scores improved from 0.552 to 0.664, whereas the control group's scores declined slightly. EQ-VAS scores also increased significantly in the intervention group. Conclusion: The MINE-based IMM intervention effectively reduced inappropriate prescribing and enhanced the quality of life in elderly patients with CHF. This technology-enabled multidisciplinary approach supports safer prescribing in geriatric care.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.